Testing Experimental Treatment for Cystic Fibrosis
common.study.values.description
“A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222”
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - ABBV-3067
Tablet or capsule taken orally
Drug - Placebo ABBV-3067
Tablet or capsule taken orally
Drug - ABBV-2222
Capsule taken orally
Drug - Placebo ABBV-2222
Capsule taken orally
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
common.study.values.clinical-trial-id
NCT03969888
participant.views.study.view.id
eVOjza
